With emerging evidence pointing to a role of IL-17 in the pathogenesis of GBS, TNF-α antagonists may lead to a rebound of Th17 cells in case series treated by anti-TNF-α, subsequently lead to an uncontrollable proinflammatory cascade [35]. The gene discussed is IL17A; the disease is Guillain-Barre syndrome.